Top Premature Ejaculation Treatments Proven Effective in 2026

Premature ejaculation (PE) may affect an estimated one in three men at some point, and is among the most common male sexual concerns worldwide. Treatment options have expanded in recent years. Men can choose among multiple approaches to prolong ejaculation and address related factors. This guide summarizes approaches supported by evidence, including dual-action combination therapy, on-demand SSRIs, topical anesthetics, pelvic floor training, and pipeline innovations, so you can identify treatments that may fit your situation, preferences, and goals. Individual results may vary. This content is educational and not a substitute for personalized medical advice.

Rugiet Go Long dual-action combination therapy

Dual-action combination therapy for PE pairs an SSRI (paroxetine), which may delay ejaculation, with a PDE5 inhibitor (tadalafil), which may support erection quality — targeting both neurological and vascular mechanisms of sexual performance in a single dose. Rugiet Go Long is built on this principle. Rugiet Go Long combines paroxetine and tadalafil in a single on‑demand dose and is prescribed via medically supervised telehealth; it is designed to simplify treatment for men seeking effects on ejaculation timing and erection confidence in a single regimen. Individual results may vary.

The rationale for combining these two drug classes is supported by clinical guidance. Paroxetine has been reported to be among the most effective SSRIs for delaying ejaculation. The European Association of Urology (EAU) guidelines note that combining PDE5 inhibitors with SSRIs may perform better than SSRI monotherapy for some men with PE. Tadalafil’s effects can persist for up to 36 hours in some individuals, which may offer greater dosing flexibility for couples.

What may make Rugiet Go Long distinct from taking separate prescriptions:

• On‑demand dosing, taken when needed rather than daily
• Up to 36 hours of effect in some users, due to tadalafil’s long half‑life
• Medically supervised telehealth prescribing, where a licensed provider reviews your health profile and tailors treatment
• Discreet home delivery, avoiding in‑person pharmacy pickup

This approach may suit men who experience premature ejaculation alongside erection concerns or performance anxiety, where both factors interact in a cycle that single‑mechanism treatments sometimes cannot break. For a deeper look at the pharmacology, Rugiet’s science explainer reviews the available evidence on combining SSRIs and PDE5 inhibitors. Individual results may vary.

On-demand SSRI: dapoxetine

Dapoxetine is a short‑acting selective serotonin reuptake inhibitor taken one to three hours before intercourse, developed for on‑demand management of premature ejaculation rather than daily use. It differs from other SSRIs because of its rapid absorption and fast elimination, which makes it practical as a when‑needed medication.

The EAU recommends considering dapoxetine as a first‑line option for lifelong PE in settings where it is available, and reviews in the literature note that dapoxetine is approved for PE in some countries. In clinical trials, dapoxetine at 30–60 mg taken one to two hours before intercourse was associated with improvements in intravaginal ejaculatory latency time (IELT) and subjective ejaculatory control compared with placebo, with benefits reported in both lifelong and acquired PE. Adding behavioral therapy to dapoxetine may further improve outcomes for some men.

Dapoxetine is generally well tolerated; reported side effects include dizziness, nausea, diarrhea, and headache, though these are uncommon at standard doses. One important regulatory note for U.S. readers: as of 2026, there was not a medication specifically approved by the U.S. Food and Drug Administration for premature ejaculation; this regulatory landscape is one reason off‑label SSRI use and integrated combination approaches are used in the United States. Individual results may vary.

Topical anesthetics: lidocaine and prilocaine sprays and creams

Topical anesthetics are medicated creams or metered‑dose sprays containing lidocaine and/or prilocaine that are applied to the penile glans before intercourse to reduce nerve sensitivity and help delay ejaculation. They offer a primarily local, on‑demand option that avoids systemic exposure for many users.

The EAU recommends lidocaine‑prilocaine spray as a first‑line option for some men with lifelong PE. Efficacy data from trials of PSD502 (marketed as Fortacin in some regions) reported a multi‑fold increase in IELT compared with placebo. Application is typically done several minutes before sex, though timing requires some planning and practice.

Topical anesthetics can be a practical starting point for men who prefer to avoid systemic medication, but they do involve trade‑offs.

Pros

• Minimal systemic exposure; medication acts locally
• Often rapid onset, with effects commonly observed within 5–10 minutes
• Available over the counter in some markets
• Easy to use and discreet

Cons

• Can reduce penile sensation and therefore sexual pleasure for some men
• Risk of transferring numbness to a partner during intercourse
• Requires precise timing relative to sexual activity
• May be used with a condom to reduce partner transfer
• Does not directly address erection quality or psychological contributors

For men whose PE is primarily driven by penile hypersensitivity and who do not have concurrent erection concerns, topical anesthetics may be an effective first step. For more complex cases, they are often more effective when combined with other approaches. Individual results may vary.

Daily or on‑demand SSRIs and clomipramine

SSRIs are widely used as first‑line pharmacologic options for PE in many countries. Off‑label SSRI use for PE involves prescribing an SSRI antidepressant, such as paroxetine, sertraline, or fluoxetine, at doses intended to delay ejaculation, even though the drugs’ primary approvals may be for depression or anxiety disorders. This class of medication forms a common pharmacological backbone of PE treatment globally.

Paroxetine has frequently been reported as one of the more potent options; a meta‑analysis cited large relative increases in IELT associated with paroxetine versus placebo. SSRIs may begin to affect ejaculation timing within 5 to 10 days for some men, though full effect is often seen after two to three weeks of consistent daily dosing. Clomipramine, a tricyclic antidepressant, is another off‑label option that some guidelines list among effective treatments.

Patient satisfaction can be mixed. A 2024 review noted that some patients report dissatisfaction with SSRIs as monotherapy because of limited benefit or bothersome side effects. This variability is one reason combination approaches — pairing an SSRI with a PDE5 inhibitor or with behavioral therapy — are commonly considered.

Individual response and tolerability vary; working with a prescriber helps match the regimen to a man’s priorities and medical history.

Combination therapy: SSRIs plus PDE5 inhibitors or behavioral approaches

Some clinical studies suggest combining modalities may produce better outcomes for certain men. Guidelines and reviews note that behavioral treatment plus drug therapy may be more effective than either alone for some patients, and that adding a PDE5 inhibitor to an SSRI can improve outcomes in men who have both ejaculation timing issues and erection concerns.

Combination therapy for PE pairs two or more interventions — for example, an SSRI with a PDE5 inhibitor, or medication with behavioral techniques — to address multiple contributing factors simultaneously. Pharmacologically, the SSRI component may raise the ejaculatory threshold by modulating serotonin centrally, while the PDE5 inhibitor may support erection confidence by enhancing blood flow. Improved erection reliability can reduce performance anxiety that accelerates ejaculation, and behavioral techniques can help consolidate gains over time.

How combination therapy may work in practice:

1. SSRI component may increase the time to climax by altering serotonergic signaling.
2. PDE5 inhibitor may support firmer, more reliable erections, which can reduce urgency and anxiety.
3. Reduced anxiety and better erection confidence can interrupt a performance‑anxiety feedback loop.
4. Behavioral techniques reinforce control skills and may sustain benefits beyond medication use.

Rugiet Go Long is an example of an on‑demand combination approach that pairs paroxetine with tadalafil in one formulation, intended to reduce the burden of managing multiple prescriptions. For men curious whether PDE5 inhibitors help with lasting longer, the evidence base is evolving and suggests they may be most useful as adjuncts, particularly when erectile concerns coexist with PE. Individual results may vary.

Behavioral and pelvic floor muscle therapies

Behavioral techniques, pelvic floor training, and counseling are recognized treatment options for PE. Non‑pharmacological approaches carry low physiological risk and can be effective on their own for mild PE or as complements to medication.

Core behavioral techniques

1. Stop‑start method: During stimulation, the man pauses stimulation when he feels close to ejaculation. After the urge decreases (often 30–60 seconds), stimulation resumes. Repeating this trains awareness and control of the pre‑ejaculatory sensation. The World Journal of Men’s Health and other sources describe stop‑start and squeeze techniques as standard behavioral options.

2. Squeeze technique: When ejaculation feels imminent, the man or partner applies firm pressure to the penis where the glans meets the shaft until the urge subsides. This partner‑assisted method builds ejaculatory awareness and can be practiced over multiple sessions.

3. Pelvic floor exercises (Kegels): Strengthening the bulbocavernosus and pubococcygeus muscles through targeted contractions may improve ejaculatory control for some men. The Mayo Clinic includes pelvic floor exercises among PE treatment options. Typical routines reported in guidance involve multiple short sets of contractions daily, with gradual progression over weeks.

Practical tips

• Masturbating one to two hours before intercourse may help delay ejaculation during partnered sex for some men.
• Brief abstinence periods can reduce performance pressure while practicing techniques.
• Thicker condoms may slightly reduce sensitivity without topical anesthetics.

Counseling and sex therapy

When psychological or relationship factors contribute to PE — stress, anxiety, unrealistic expectations, or partner dynamics — sex therapy can improve outcomes. Counseling provides a structured space to address these contributors and is often most effective when combined with pharmacological treatment. For men navigating PE within a relationship, couples‑based approaches may strengthen communication and sexual functioning. Individual results may vary.

Emerging treatments: novel on‑demand agents and device‑based options

The PE treatment pipeline includes investigational agents and device approaches that are under study:

• KH‑001 (investigational on‑demand oral agent) is being developed for on‑demand dosing and early reports describe rapid onset; pivotal trials are ongoing and results remain preliminary.
• Nerve modulation devices, including transcutaneous electrical stimulation and neuromodulation technologies, are being explored to alter ejaculatory reflex pathways. Preliminary data show potential but larger, rigorous trials are needed before routine recommendation.
• Glans augmentation with hyaluronic acid filler has been studied in small series and some reports suggest reduced sensitivity; durability and long‑term safety continue to be investigated.
• Tramadol (off‑label) can delay ejaculation in some men, but the EAU and other reviews note limited long‑term safety evidence and dependence risk, which constrains its routine use.

While these approaches are under investigation, clinicians currently rely most on established, evidence‑backed options such as on‑demand and daily SSRIs, topical anesthetics, behavioral therapies, and medically supervised combination approaches. Rugiet continues to track innovations for potential future inclusion as robust data emerge. Individual results may vary.

Choosing the right premature ejaculation treatment

Selecting the right approach depends on personal factors, clinical context, and goals. Surveys of urologists and guideline recommendations often use IELT (intravaginal ejaculatory latency time) and symptom burden to guide treatment selection, but the ideal plan varies by individual.

Key decision factors to consider:

• PE subtype: Lifelong PE often responds well to pharmacotherapy as a first‑line approach; acquired PE may prompt evaluation for underlying causes such as thyroid dysfunction, prostatitis, or medication side effects before selecting a treatment.
• Comorbid erection concerns: When PE and erection difficulties occur together, a combination approach that addresses both may be preferable.
• On‑demand vs. daily preference: On‑demand options (topical anesthetics, dapoxetine where available, or on‑demand combination pills) support spontaneity. Daily SSRIs provide consistent baseline control but require ongoing commitment.
• Side‑effect tolerance: Topical anesthetics avoid systemic effects for many users. SSRIs may cause broader side effects (nausea, fatigue, changes in libido) but can provide stronger ejaculatory delay for some men.
• Partner and relationship factors: Behavioral techniques and counseling often involve partner participation and can strengthen sexual communication and outcomes.

The most effective path forward usually begins with an honest conversation with a healthcare provider who can assess medical history, comorbidities, and treatment goals. Rugiet’s online assessment connects men with licensed providers who may recommend a personalized plan — whether that includes an on‑demand combination approach, behavioral strategies, or a combination. Rugiet’s care model emphasizes individualization and clinical oversight. Individual results may vary.

Frequently asked questions

What treatments are shown to be effective for premature ejaculation?

Treatments supported by clinical studies include SSRIs such as paroxetine, topical anesthetics like lidocaine‑prilocaine sprays, and combination approaches that pair an SSRI with a PDE5 inhibitor or with behavioral therapy. Combination strategies may offer additional benefit for men who have both ejaculation timing issues and erection concerns. Individual results may vary.

How quickly do different premature ejaculation treatments work?

Topical anesthetics often take effect within 5–10 minutes. On‑demand oral treatments like dapoxetine typically take effect within one to three hours. Daily SSRIs may begin to change ejaculation timing within 5 to 10 days for some men, with fuller effect over two to three weeks. On‑demand combination pills are intended for same‑day effectiveness for many users. Individual results may vary.

Can premature ejaculation be treated without medication?

Yes. Behavioral techniques such as the stop‑start method, squeeze technique, and pelvic floor exercises can help delay ejaculation without medication for some men. Sex therapy or counseling may improve outcomes when psychological or relationship factors contribute. These approaches may work well for mild PE and are often used alongside pharmacological treatment. Individual results may vary.

Are there side effects associated with PE treatments?

Side effects vary by treatment type. SSRIs may cause nausea, dizziness, drowsiness, or changes in libido. Topical anesthetics can reduce penile sensation or cause numbness in a partner if transferred. PDE5 inhibitors may produce headache, flushing, or nasal congestion. A healthcare provider can help select an option that balances potential benefits and side effects.

Can premature ejaculation treatments also address erection concerns?

Some combination therapies that include a PDE5 inhibitor alongside an SSRI are designed to address both ejaculation timing and erection confidence in the same regimen. This approach may be helpful when both issues occur together, as they can interact through anxiety and performance pressure. Individual results may vary.

Sources

• Research Report: Top Premature Ejaculation Treatments Proven Effective in 2026